Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 5 Jul 2012 |
| Orion upgrades full-year outlook for 2012 | 3 Jul 2012 |
| U.S. District Court gives decision on Precedex® patent litigation | 1 May 2012 |
| Orion sues Mylan in the U.S. to enforce its U.S. patents covering the proprietary drug Stalevo® | 26 Apr 2012 |
| Orion Group Interim Report January-March 2012 | 24 Apr 2012 |